A recent study reveals that patients who discontinue popular weight-loss injections like Mounjaro or Wegovy may regain shed pounds far faster than those who end conventional diet and exercise regimens.
Research printed in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing such medications should be aware of the risk of fast rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
That rate of regain implies a reversion to original mass in about one and a half years.
Weighing Approaches
The research, which looked at dozens of trials involving thousands of participants, contrasted the results of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise usually experience a more gradual creep back—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Experts suggest the mechanism of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to hunger is unsuppressed, making overeating much more probable."
A Chronic Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, due to the significant potential of weight regain, the treatment is often life-long.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the long-term nature of excess weight," akin to managing conditions like high blood pressure.
Patient Accounts
People who have discontinued the medication explain a sudden resurgence of cravings.
"It was like a switch activating and you become extremely hungry," said one woman.
The struggle is exacerbated if patients have not adopted lasting lifestyle or habit modifications during therapy.
Growing Use
Figures show that millions of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is greater among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and lasting health benefits likely depends on combined behavioural management.
